Novo Nordisk shares fall on latest trial results for new obesity drug

Share
https://residentialbusiness.com/income/topic/6462-novo-nordisk-shares-fall-on-latest-trial-results-for-new-obesity-drug/
Followers

Posted March 10Mar 10

Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema

https://residentialbusiness.com/income/topic/6462-novo-nordisk-shares-fall-on-latest-trial-results-for-new-obesity-drug/

Followers

Go to topic listing

Ready to Post a Comment or Start a Topic?

If you’re serious about building or launching your business, don’t just browse— take action now.

Join the platform that’s helping new and remote entrepreneurs thrive.

Ready to unlock more? Explore our exclusive site features and see what tools are waiting for you.

Want to accelerate your journey? Subscribe to our expanded forum and go from learning to earning.

Your business deserves momentum. Let’s build it together.

Sign In

Novo Nordisk shares fall on latest trial results for new obesity drug

Featured Replies

Ready to Post a Comment or Start a Topic?

Account

Navigation

Search